^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

ABSK043

i
Other names: ABSK043, ABSK-043, ABSK 043
Associations
Company:
Abbisko
Drug class:
PD-L1 inhibitor
Related drugs:
Associations
5d
A Phase 2 Clinical Study of ABSK061 and ABSK043 (clinicaltrials.gov)
P2, N=202, Recruiting, Abbisko Therapeutics Co, Ltd | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3)
|
FGFR3 overexpression • FGF3 overexpression
|
ABSK043 • ABSK061
24d
New P2 trial • Combination therapy • Metastases
|
Ivesa (firmonertinib) • ABSK043
2ms
A Phase 2 Clinical Study of ABSK061 and ABSK043 (clinicaltrials.gov)
P2, N=202, Not yet recruiting, Abbisko Therapeutics Co, Ltd
New P2 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • FGFR2 (Fibroblast growth factor receptor 2) • FGFR3 (Fibroblast growth factor receptor 3)
|
FGFR3 overexpression • FGF3 overexpression
|
ABSK043 • ABSK061
over1year
First-in-human dose-escalating study of ABSK043, a novel and oral small-molecule inhibitor of PD-L1, in patients with advanced solid tumors (ESMO 2023)
On-target PD effects were consistent with PD-L1 inhibition and data reported by anti-PD-(L)1 mAbs. Preliminary anti-tumor activity was observed, and further studies are warranted to explore the efficacy in a larger number of patients.
Clinical • P1 data • Metastases
|
MSI (Microsatellite instability) • IFNG (Interferon, gamma) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • IL2 (Interleukin 2)
|
MSI-H/dMMR
|
ABSK043
2years
Broad anti-tumor activity of a potent and selective small molecule antagonist of PD-L1 ABSK043 in combination with other agents in preclinical models (SITC 2022)
Results ABSK043 demonstrated strong in vivo synergy with several therapeutic agents such as carboplatin, a key component of the widely used CRC standard-of care chemotherapy treatment regimen, as well as other target therapy or immune-oncology agents. Conclusions Taken together, these data for the first time demonstrated broad combination synergy of a small molecule PD-L1 antagonist with other agents and provided basis for potential clinical evaluation of these combination treatment for cancer patients.
Preclinical • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
carboplatin • ABSK043
over2years
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor (clinicaltrials.gov)
P1, N=60, Recruiting, Abbisko Therapeutics Co, Ltd | Not yet recruiting --> Recruiting
Enrollment open
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
ABSK043
over3years
Clinical • New P1 trial
|
MSI (Microsatellite instability)
|
MSI-H/dMMR
|
ABSK043